Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?

Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.

    What Falling Estimates & Price Mean for ChromaDex (CDXC)

    ChromaDex (CDXC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

      Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing

      Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.

        Inovio Initiates Phase II Study on Pipeline Drug VGX-3100

        Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.

          Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?

          Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

            AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

            AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

              ResMed Releases Positive U.S. & U.K. Study Data on COPD

              ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.

                Here's Why You Should Invest in Illumina (ILMN) Stock Now

                Illumina (ILMN) gains ground on product launches and international prospects.

                  Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?

                  Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.

                    Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

                    Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

                      Sweta Killa headshot

                      Should You Invest in the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)?

                      Sector ETF report for PBE

                        QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff

                        QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.

                          Medtronic Initiates Study on DES for Expanded Use in the US

                          Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.

                            Illumina Takes Over Edico Genome, Fortifies NGS Platform

                            Illumina (ILMN) proceeds with deals to boost NGS platform.

                              Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

                              FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

                                Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

                                Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

                                  Tirthankar Chakraborty headshot

                                  5 Winning Stocks With Superb Efficiency Level

                                  A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

                                    Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina

                                    Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina

                                      Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View

                                      Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.

                                        5 Top Stocks Showing Promise of an Earnings Beat

                                        Bet on five stocks that are likely to outdo earnings estimates.

                                          Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss

                                          Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.

                                            Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

                                            Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

                                              Tirthankar Chakraborty headshot

                                              4 Top Efficient Stocks to Buy for Stellar Returns

                                              A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.

                                                Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance

                                                Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.

                                                  Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo

                                                  Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.